Pacific Biosciences of California, Inc. (PACB) stock forecast & analysis
1.96
NasdaqGS · USDDelayed by 15 minutes
Down: -0.01, -0.5%
1.93Down: -0.03, -1.5%
4 analyses
Latest analysis: · verdict locked
- Open
- 1.99
- Previous close
- 1.97
- Day range
- 1.84 – 2.00
- 52-week range
- 1.07 – 3.44
- Volume (shares)
- 7.02M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 312.24M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 2.20
- Market cap
- 611.98M
Market Scanner’s AI analysis of Pacific Biosciences of California, Inc. (PACB), updated November 2026: Cathie Wood's increased stake and strategic partnerships with Verily Health and TychoBio contrasted with ongoing revenue declines and significant net losses for PACB.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Pacific Biosciences of California, Inc. (PACB) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Cathie Wood's increased stake and strategic partnerships with Verily Health and TychoBio contrasted with ongoing revenue declines and significant net losses for PACB.
Recent analyses for PACB covered significant price momentum, with the stock trading well above its 50-day and 200-day moving averages, alongside notable short-term gains. The company's financial performance showed a year-over-year revenue decline and substantial net losses, with negative shareholder equity. News highlighted strategic collaborations and an increased stake by Cathie Wood, alongside market performance that sometimes outpaced broader indices.
PACB news & sentiment
News reports highlighted PACB's stock resilience and outperformance of the broader market at times, alongside significant price momentum. However, other reports noted sharp stock declines and underperformance relative to the market, with reasons for the dip unclear.
PACB technical picture
PACB's price action showed significant upward momentum, trading well above its 50-day and 200-day moving averages. Momentum indicators, including RSI, MFI, and MACD, displayed varied signals across different reports, ranging from overbought conditions to decreasing bullish momentum and neutral territory.
Fundamentals
The company's revenue has shown a year-over-year decline, and it is experiencing significant net losses with negative profit and operating margins. Shareholder equity is also negative, indicating a concerning trend. Liquidity ratios, however, appear strong.
Factors discussed — upside
- Significant price appreciation above key moving averages.
- Cathie Wood's Ark Invest increased stake in the company.
- Strategic collaboration with Verily Health to advance biomedical AI.
- Strategic partnership with TychoBio for AI-driven RNA therapeutics.
Factors discussed — risks
- Year-over-year quarterly revenue decline.
- Significant net losses and negative profit margins.
- Negative total shareholder equity.
- Stock price declined more than the market on certain dates.
- Technical momentum
- Financial performance
- Strategic partnerships
- Institutional investment activity
Summary updated .
PACB technical indicators
Common technical indicators for PACB, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 2.01 | Price below |
| 10-day exponential moving average | 2.20 | Price below |
| Relative strength index (14-day) | 43.01 | Neutral |
| MACD line (12/26/9) | 0.0151 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 1.73 – 2.85 | Price inside the bands |
PACB stock forecast — AI outlook
The most recent historical sample analysis of PACB recorded this AI decision distribution. Newer analyses are locked — get the current verdict.
Buy 10%Hold 20%Sell 70%
As of
Analyses
Historical, AI-generated samples of past PACB.US analyses — one per day, shown for context, not current guidance. Newer reports are locked; sign in to read them or generate a fresh one.
Neutral
The stock is experiencing strong recent upward momentum with prices trading significantly above key moving averages and indicators showing high buying pressure. However, recent revenue has declined year-over-year, and the company has negative profit margins and returns on equity.
Neutral
Market indicators show mixed signals with strong short-term momentum and buying pressure, but the price trading above the upper Bollinger Band suggests potential overbought conditions. Fundamentally, the company faces declining revenue and significant losses, resulting in negative shareholder equity. Recent news highlights a strategic partnership and neutral coverage initiation, but the stock has underperformed the market ahead of upcoming earnings.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-11-01 PACB.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Pacific Biosciences of California, Inc.?
- The bull case for PACB centers on significant price momentum, with the stock trading well above key moving averages, alongside strategic collaborations with Verily Health and TychoBio aimed at advancing AI in genomics and therapeutics. Additionally, Cathie Wood's Ark Invest has increased its stake in the company, signaling institutional interest.
- What are the risks for Pacific Biosciences of California, Inc.?
- Risks for PACB include ongoing year-over-year revenue declines and substantial net losses, coupled with negative shareholder equity. The stock has also experienced periods of underperformance relative to the broader market, indicating potential investor concerns despite positive developments.
- Is Pacific Biosciences of California, Inc. bullish or bearish?
- Recent AI analyses of Pacific Biosciences of California, Inc. examined factors on both sides. Discussed upside: The bull case for PACB centers on significant price momentum, with the stock trading well above key moving averages, alongside strategic collaborations with Verily Health and TychoBio aimed at advancing AI in genomics and therapeutics. Additionally, Cathie Wood's Ark Invest has increased its stake in the company, signaling institutional interest. Discussed risks: Risks for PACB include ongoing year-over-year revenue declines and substantial net losses, coupled with negative shareholder equity. The stock has also experienced periods of underperformance relative to the broader market, indicating potential investor concerns despite positive developments. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Pacific Biosciences of California, Inc.?
- News reports highlighted PACB's stock resilience and outperformance of the broader market at times, alongside significant price momentum. However, other reports noted sharp stock declines and underperformance relative to the market, with reasons for the dip unclear.
- What is the Pacific Biosciences of California, Inc. (PACB) stock forecast?
- Market Scanner publishes historical AI analysis samples rather than a live forecast. The most recent sample for Pacific Biosciences of California, Inc. (PACB), dated 2026-10-16, recorded an AI decision distribution of Buy 10%, Hold 20%, and Sell 70%. It is a dated historical sample shown for context, not current guidance.
- What is the Pacific Biosciences of California, Inc. (PACB) stock prediction for 2026?
- Market Scanner does not make price predictions for 2026. As of 2026-10-16, its most recent historical sample analysis of Pacific Biosciences of California, Inc. (PACB) recorded an AI decision distribution of Buy 10%, Hold 20%, and Sell 70%. Newer analyses are available after sign-in.
- How does Market Scanner analyse Pacific Biosciences of California, Inc.?
- Every analysis of Pacific Biosciences of California, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Pacific Biosciences of California, Inc.?
The bull case for PACB centers on significant price momentum, with the stock trading well above key moving averages, alongside strategic collaborations with Verily Health and TychoBio aimed at advancing AI in genomics and therapeutics. Additionally, Cathie Wood's Ark Invest has increased its stake in the company, signaling institutional interest.
What are the risks for Pacific Biosciences of California, Inc.?
Risks for PACB include ongoing year-over-year revenue declines and substantial net losses, coupled with negative shareholder equity. The stock has also experienced periods of underperformance relative to the broader market, indicating potential investor concerns despite positive developments.
Is Pacific Biosciences of California, Inc. bullish or bearish?
Recent AI analyses of Pacific Biosciences of California, Inc. examined factors on both sides. Discussed upside: The bull case for PACB centers on significant price momentum, with the stock trading well above key moving averages, alongside strategic collaborations with Verily Health and TychoBio aimed at advancing AI in genomics and therapeutics. Additionally, Cathie Wood's Ark Invest has increased its stake in the company, signaling institutional interest. Discussed risks: Risks for PACB include ongoing year-over-year revenue declines and substantial net losses, coupled with negative shareholder equity. The stock has also experienced periods of underperformance relative to the broader market, indicating potential investor concerns despite positive developments. These are descriptive observations, not a recommendation.
What is the latest sentiment on Pacific Biosciences of California, Inc.?
News reports highlighted PACB's stock resilience and outperformance of the broader market at times, alongside significant price momentum. However, other reports noted sharp stock declines and underperformance relative to the market, with reasons for the dip unclear.
What is the Pacific Biosciences of California, Inc. (PACB) stock forecast?
Market Scanner publishes historical AI analysis samples rather than a live forecast. The most recent sample for Pacific Biosciences of California, Inc. (PACB), dated 2026-10-16, recorded an AI decision distribution of Buy 10%, Hold 20%, and Sell 70%. It is a dated historical sample shown for context, not current guidance.
What is the Pacific Biosciences of California, Inc. (PACB) stock prediction for 2026?
Market Scanner does not make price predictions for 2026. As of 2026-10-16, its most recent historical sample analysis of Pacific Biosciences of California, Inc. (PACB) recorded an AI decision distribution of Buy 10%, Hold 20%, and Sell 70%. Newer analyses are available after sign-in.
How does Market Scanner analyse Pacific Biosciences of California, Inc.?
Every analysis of Pacific Biosciences of California, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2, gpt-low
Run a fresh PACB.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.